Community Forward News
2 articles
growth-positive
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
NeuroSense Therapeutics Ltd., a biotechnology company focused on neurodegenerative diseases, is advancing its investigational therapy, PrimeC, for ALS. In a live webcast hosted by actor and ALS advocate Aaron Lazar, NeuroSenses CEO Alon Ben-Noon discussed the promising potential of PrimeC, which has shown efficacy in Phase 2a trials. The webcast also covered NeuroSenses regulatory progress in Canada and a binding term sheet with a pharmaceutical partner. PrimeC, a combination of ciprofloxacin and celecoxib, targets ALS mechanisms and has received Orphan Drug Designation from the FDA and EMA. The event aims to engage the ALS community, media, and investors, highlighting NeuroSenses commitment to addressing unmet medical needs in neurodegenerative diseases.
Product StagePartners
growth-positive
Israeli AI companies don't yet pay the huge signing on fees seen in Silicon Valley but AI experts are top of the tree in Tel Aviv's well-paid tech sector.
The article discusses the intense competition among major tech companies like Meta, Google, and OpenAI to acquire top AI talent, offering substantial salaries and benefits. Google has made significant talent acquisitions, including two executives from Windsurf and 30 executives from Character for $2.5 billion. The demand for AI professionals in Israel is growing, with salaries increasing significantly. However, there is a shortage of experienced AI professionals, leading to high salaries and creative incentives. The article highlights the need for a national program to address the talent gap in AI, similar to the cybersecurity field. The demand for AI integration in enterprises is also rising, with managerial positions offering high salaries.
Acquisition
